Cargando…
Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids
The spectrum of non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis commonly associated with obesity, to non-alcoholic steatohepatitis, which can progress to fibrosis, cirrhosis and hepatocellular carcinoma. Recent reports have indicated the crucial role of gut microbiota...
Autores principales: | Naito, Yuji, Ushiroda, Chihiro, Mizushima, Katsura, Inoue, Ryo, Yasukawa, Zenta, Abe, Aya, Takagi, Tomohisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417793/ https://www.ncbi.nlm.nih.gov/pubmed/32801462 http://dx.doi.org/10.3164/jcbn.20-39 |
Ejemplares similares
-
Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice
por: Ushiroda, Chihiro, et al.
Publicado: (2019) -
Exercise-acclimated microbiota improves skeletal muscle metabolism via circulating bile acid deconjugation
por: Aoi, Wataru, et al.
Publicado: (2023) -
Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
por: Singh, Neha Atulkumar, et al.
Publicado: (2016) -
Effects of molecular hydrogen-dissolved alkaline electrolyzed water on intestinal environment in mice
por: Higashimura, Yasuki, et al.
Publicado: (2018) -
Antioxidant and antiviral activities of lipophilic epigallocatechin gallate (EGCG) derivatives
por: Zhong, Ying, et al.
Publicado: (2012)